多替拉韦联合拉米夫定简化方案治疗初治HIV感染者真实世界研究  

A real-world study of the simplified regimen of dotilavir combined with lamivudine in the treatment of newly infected people with HIV

作　　者：李春娜[1] 洪仲思[1] 陈萍[1] 夏瑾瑜[1] 邓丽斯 LI Chun-na;HONG Zhong-si;CHEN Ping;XIA Jin-yu;DENG Li-si(Infection Disease Prevention Center,the Fifth Affiliated Hospital,Sun Yat-sen University,Zhuhai 519000,China)

机构地区：[1]中山大学附属第五医院感染病防治中心,珠海519000

出　　处：《传染病信息》2022年第6期502-505,共4页Infectious Disease Information

基　　金：珠海市科技局面上项目(ZH2202200017HJL);中山大学热带病防治研究教育部部重点实验室2018年度开放课题(2018kfkt)。

摘　　要：目的初步观察多替拉韦联合拉米夫定简化方案治疗初治HIV感染者的临床疗效。方法采用前瞻性观察研究方法,筛选我院门诊确诊的HIV/AIDS患者,接受多替拉韦联合拉米夫定简化方案治疗,观察治疗期间CD4^(+)T细胞计数、CD4/CD48比值、HIV载量及炎症因子的变化情况。结果27例患者在治疗12周时病毒抑制率为62.96%,24周和48周时分别为92.31%和100%;CD4^(+)T细胞计数在治疗12周时上升为(340.53±235.39)个/μl,24周时上升为(430.26±291.71)个/μl(P均<0.05);治疗前44.44%的患者合并机会性感染,其治疗前升高的炎症因子在治疗后均逐渐下降。结论多替拉韦联合拉米夫定简化治疗初治的HIV/AIDS患者可以获得较高的病毒抑制率,尤其可以作为晚期患者的优化方案。Objective This study aimed to evaluate the efficacy of a two-drug regimen comprising dolutegravir(DTG)and lamivudine(3TC)for the treatment of HIV infection in HAART-naive adults.Methods We performed a prospective real world study of HIV-infected patients on dolutegravir plus lamivudine regimen treatment and analysed their change of plasma HIVRNA level,CD4^(+)T cell count,CD4/CD8 ratio and inflammatory factors.Results Twenty-seven antiretroviral-naive patients were enrolled.The viral suppression rate was 62.96%at week 12,92.3% at week 24 and 100%at week 48.CD4^(+)T cell count was(340.53±235.39)/μl at week 12(P<0.05)and(430.26±291.71)/μl at week 24(P<0.05).Besides,before treatment,44.44% patients had opportunistic infectionand increased inflammatory factors which decreased after treatment.Conclusions The two-drug regimen(Dolutegravir plus lamivudine)achieved a high viral suppression rate in antiretroviral-naive adults,especially for advanced patients.

关 键 词：HIV AIDS 多替拉韦 拉米夫定 二联简化方案 真实世界研究 临床疗效 安全性研究 不良反应 优化治疗 

分 类 号：R512.91[医药卫生—内科学]